Consolidated Revenue for the quarter was $10.1 million, representing an increase of 1% compared to Q4 2019. Prescriptions filled during Q4 totaled approximately 134,000, representing an increase of 1% compared to Q4 2019. 340B revenue was approximately $879k, representing a sharp increase of 200% compared to Q4 2019. EBITDA increased 104% to $667k in Q4 2020 when compared to the same period in 2019.
Financial Highlights for Fiscal Year Ended Dec 31, 2020 Consolidated Revenue was $40.3 million, representing an increase of 22% compared to fiscal 2019. Prescriptions filled was approximately 530,000, representing an increase of 16% compared to fiscal 2019. 340B revenue was approximately $2.8 million, representing a sharp increase of over 300% compared to fiscal 2019. COVID testing revenue was approximately $600K, most of which was earned in Q4 2020.